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Abstract
Pulmonary embolism (PE) is a life-threatening condition and a leading cause of morbidity and mortality. There have been many
advances in the field of PE in the last few years, requiring a careful assessment of their impact on patient care. However, variations
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in recommendations by different clinical guidelines, as well as lack of robust clinical trials, make clinical decisions challenging. The
Pulmonary Embolism Response Team Consortium is an international association created to advance the diagnosis, treatment, and
outcomes of patients with PE. In this consensus practice document, we provide a comprehensive review of the diagnosis,
treatment, and follow-up of acute PE, including both clinical data and consensus opinion to provide guidance for clinicians caring
for these patients.
Keywords
acute pulmonary embolism, venous thromboembolism, pulmonary embolism response team, systemic thrombolysis, catheterdirected thrombolysis, embolectomy, inferior vena cava filter, chronic thromboembolic pulmonary hypertension
Date received: 25 February 2019; revised: 30 April 2019; accepted: 30 April 2019.

Introduction
There are an estimated 900 000 cases of venous thromboembolism (VTE) every year in the United States, 150 000 to
250 000 pulmonary embolism (PE)-related hospitalizations and
60 000 to 100 000 deaths, making it the third most common
cause of cardiovascular death.1 Once a PE is diagnosed, risk
stratification is necessary to define appropriate management.
Treatments can range from anticoagulation alone, catheterdirected thrombolysis, full-dose systemic thrombolysis (ST),
reduced-dose ST, catheter embolectomy, surgical embolectomy, and/or mechanical circulatory support such as extracorporeal membrane oxygenation (ECMO). It has been recognized
that advanced treatment options used for PE vary by institution,
medical specialty, and operator experience.2 Variations or
ambiguity in treatment recommendations in clinical guidelines
published by societies such as the American College of Chest
Physicians (ACCP),3 American Heart Association (AHA),4
and/or European Society of Cardiology (ESC),5 as well as lack
of robust clinical trials make advanced treatment decisions
challenging.
To aid physicians caring for patients with acute PE, consensus diagnosis, treatment, and follow-up algorithms were developed by the Pulmonary Embolism Response Team (PERT)
consortium. A writing group was established by the PERT
Clinical Practice and Protocols Development Committee. The
writing group was divided into the topics focused in this manuscript based on each member content expertise. Each group
systematically reviewed and summarized the relevant published literature and incorporated this information into a manuscript. In areas where high-quality evidence was lacking, the
committee carefully consolidated algorithms from multiple
institutions with PERT programs and administered a practice
survey (Supplemental Material) in our PERT annual meeting
and incorporated them into the manuscript. Differences in
opinion were dealt with face-to-face meetings and subsequently through electronic and telephone communications. The
final document and algorithms reflect the consensus opinion of
the entire committee.
The purpose of these algorithms is to provide practical,
evidence-based, and expert recommendations from across disciplines and institutions, for the management of PE that can be
applied in the real world (Table 1). We present the structure of

the PERT activation (Figure 1), the diagnosis (Figure 2), treatment (Figure 3), and follow-up (Figure 4) algorithms of the
PERT Consortium as well as outlining the rationale and evidence or expert opinion to support each decision.

Pulmonary Embolism Response Team
The concept of multidisciplinary team collaboration for serious
diseases has been implemented successfully for the last decade
in the “Heart Team” approach in complex percutaneous coronary intervention and transcatheter aortic valve replacement
and it is supported by the AHA and American College of Cardiology guidelines.6-9 In response to increasing patient complexity and increasing therapeutic alternatives, there has been a
rise in the development of multidisciplinary groups of clinicians with expertise in the diagnosis and medical, surgical, and
interventional management of PE who collaborate in a novel
way to improve patient care. This multidisciplinary team
approach is termed the PERT.
Pulmonary Embolism Response Team structure and
approaches vary by institution and may involve members
from cardiac surgery, cardiac imaging, interventional and
noninterventional cardiology, critical care, emergency medicine, hematology, clinical pharmacy, pulmonary, diagnostic
and interventional radiology, vascular medicine, and vascular
surgery.2,10 A PERT is typically activated via a single contact
to a hospital’s central call service or designated phone number
(or pager) which triggers a prompt patient evaluation by the
on-call clinician who gathers relevant clinical information
(Figure 1). Following that initial evaluation, when the
decision is not immediately clear, and in order to facilitate
real-time discussion and generate shared decision-making
recommendations, a virtual multidisciplinary meeting or conference call among all PERT members is often held. Finally,
the consensus plan of action is rapidly presented to the referring clinician. Pulmonary Embolism Response Teams may
also coordinate outpatient follow-up care and serve as platform for clinical research.
The National PERT Consortium was established in 2015
when different institutions across the United States met in Boston, Massachusetts, with the intent to collaborate, guide, and
influence PE management and research. Currently, the concept
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Table 1. Executive Summary of the Diagnosis, Treatment, and Follow-Up Recommendations From the Pulmonary Embolism Response Team
Consortium.
Pulmonary Embolism Response Team (PERT)
1. Utilize a multidisciplinary Pulmonary Embolism Response Team (PERT) in patients with high or intermediate-risk PE, as well as for PE
patients in whom there is uncertainty regarding treatment.
Diagnosis, Imaging, and Risk Stratification of Pulmonary Embolism
2. Use a combination of low- or intermediate- pretest probability, the PERC rule and D-dimer testing to rule out PE without imaging.
3. When possible, use CTA to diagnose acute PE in patients with low or intermediate pretest probability and a positive D-dimer, or high
pretest probability.
4. Echocardiography and/or portable V/Q scan, when available, should be considered when there are contraindications to or an inability to
obtain CTA. Additionally, duplex ultrasonography should be considered to confirm the presence, acuity, and extent of VTE.
5. Once PE is diagnosed, risk stratification is recommended using a composite of clinical appearance, systolic blood pressure, heart rate,
respiratory rate, respiratory rate, oxygen requirement, PESI or sPESI, imaging for RV dysfunction (CTA or echocardiography) and/or
biomarkers (troponin, BNP or NT-pro-BNP).
Treatment of Pulmonary Embolism
Anticoagulation
6. Anticoagulation should be initiated as soon as PE is diagnosed unless contraindicated.
7. Anticoagulation should be initiated even prior to the confirmed diagnosis when the clinical suspicion of acute PE is high and the bleeding
risk is low.
8. Utilize evidence-based institution-specific anticoagulation guidelines to assist in anticoagulant choice, dosing, administration, and
appropriate laboratory monitoring strategies to achieve therapeutic anticoagulation as quickly as possible.
Systemic Thrombolysis (ST)
9. Consider full-dose ST in:
9.1. High-risk PE without contraindications to ST.
10. Consider reduced-dose ST in:
10.1 High-risk PE with relative contraindications to thrombolysis.
10.2 Selected intermediate-risk PE in select patients with evidence of or risk for clinical deterioration based on vital signs, severity of
RV dysfunction, tissue perfusion, and/or gas exchange, and presence of low bleeding risk.
11. Consider ST in patients with cardiac arrest and suspected PE.
12. Consider ST in selected patients with intermediate or high-risk PE with thrombus-in-transit.
Catheter-Directed Therapy
13. Consider catheter-directed thrombolysis (CDL) in:
13.1 Intermediate-high risk PE with risk for clinical deterioration based on vital signs, severity of RV dysfunction, tissue perfusion,
and/or gas exchange, and without absolute contraindication to thrombolysis.
13.2 High-risk PE with relative contraindications to ST.
14. Consider catheter embolectomy in:
14.1 Intermediate high-risk PE with risk for clinical deterioration based on vital signs, severity of RV dysfunction, tissue perfusion,
and/or gas exchange, with absolute or relative contraindications to thrombolysis.
14.2 High-risk PE with absolute contraindications to ST.
14.3 After failed ST or CDL.
14.4 Thombus-in-transit in the right atrium or right ventricle (AngioVac system).
Surgical Embolectomy (SPE)
15. Consider SPE in:
15.1 High-risk PE with contraindications to, or failure of ST or CDL.
15.2 Intermediate-high risk PE, with contraindications to, or failure of ST or CDL, with risk for clinical deterioration based on vital
signs, severity of RV dysfunction, tissue perfusion, and/or gas exchange.
15.3 Right-heart thrombi, especially with high thromboembolic burden.
15.4 Thrombus-in-transit across a patent foramen ovale (PFO).
Mechanical Hemodynamic Support
16. Consider mechanical hemodynamic support in high-risk PE with cardiac arrest, refractory shock, contraindications to, and/or failure of
ST.
Inferior Vena Cava (IVC) Filters
17. Consider an IVC filter for patients with contraindications to or failure of therapeutic anticoagulation and for highly selected patients
with intermediate or high-risk PE.
18. Consider an IVC filter in select patients when large, free-floating, proximal DVT is identified.
Pulmonary Embolism Follow-Up
19. Pulmonary embolism patients should have a short interval follow-up visit (2 weeks-3 months) post-PE, or sooner if symptoms or patient
complexity suggests the need for this. Expert follow up with the PERT team is recommended.
20. The initial postdischarge visit should focus on the patient’s clinical status, anticoagulation regimen (type, dose, duration, compliance, and
tolerance), consideration for filter removal, evaluation of thrombophilia, and age-appropriate cancer screening.
21. Patients with persistent or recurrent symptoms, particularly after 3 months, merit follow-up testing.
22. If CTEPH is highly suspected or confirmed, the patient should be referred to an expert CTEPH center.
Abbreviations: BNP, brain natriuretic peptide; CDL, catheter directed thrombolysis; CTA, chest computed tomographic angiography; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep venous thrombosis; IVC, inferior vena cava; PE, pulmonary embolism; PERT, pulmonary embolism response team;
PESI, pulmonary embolism severity index; sPESI, simplified pulmonary embolism severity index; RV, right ventricular; SPE, surgical pulmonary embolectomy; ST,
systemic thrombolysis; V/Q, ventilation/perfusion scan; VTE, venous thromboembolism.
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Figure 1. PERT activation. PERT indicates Pulmonary Embolism Response Team.

Figure 2. Pulmonary embolism diagnosis algorithm.

of PERT has been adopted in more than 100 centers worldwide.
A framework was created by establishing committees to structure the PERT Consortium: Governance, Research, Education,
Clinical Practice and Protocol Development and Communication. One of the most important goals of the PERT Clinical
Practice and Protocols Development Committee is to characterize consensus practice for clinical care. The algorithms
include clinical evidence and expert recommendations from

across disciplines and institutions. This manuscript details the
rationale for these consensus algorithms.
Recommendation:
1.

Utilize a multidisciplinary Pulmonary Embolism
Response Team (PERT) in patients with high or
intermediate-risk PE, as well as for PE patients in
whom there is uncertainty regarding treatment.
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Figure 3. Pulmonary embolism treatment algorithm.

Figure 4. Pulmonary embolism follow-up algorithm.

Diagnosis, Imaging, and Risk Stratification of Pulmonary
Embolism
A thorough history is the first step in suspected acute PE.
Patients may experience chest discomfort, palpitations, dyspnea,
dizziness or syncope, extremity pain, or swelling. Physical

examination findings of PE may include tachypnea, tachycardia,
jugular venous distension, parasternal heave, augmented second
heart sound, right-sided S3, tricuspid regurgitation murmur, pulsatile liver, peripheral edema and chest wall, back, or flank
tenderness (pulmonary infarction). Most clinical presentations
are nonspecific and may lead to frequent misdiagnosis.11,12

6
Findings of PE are rarely detected on chest radiography but
if present, include Hampton hump (wedge-shaped airspace
opacity indicative of infarct) or Westermark sign (prominent
proximal pulmonary artery [PA] with reduction in more peripheral blood vessel markings). On electrocardiography, the
most common sign of PE is sinus tachycardia or atrial fibrillation, however some well-described though insensitive signs of
right heart strain include S1Q3T3, anterior precordial T-wave
inversions, and either inferior or anterior precordial STsegment elevation.13
After a comprehensive history and physical examination,
determining the pretest probability of PE is the next step in
diagnosis. The 2 most utilized and validated clinical decision
rules are the Geneva score and the Wells’ score.14,15 These
classify pretest probability of PE into low-, intermediate- or
high-probability (or PE likely or unlikely). D-dimer testing is
highly sensitive and can rule out PE in patients with low or
intermediate pretest probability.16 Age- and risk-adjusted
D-dimer testing has higher specificity than the typical cutoff
of 500 mg/L and may be useful to exclude PE in those patients
with low-probability or PE-unlikely.17
For patients with low pretest probability of PE, the Pulmonary Embolism Rule-out Criteria (PERC) rule may be used to
identify patients for whom no testing is indicated.18 Imaging is
recommended for those patients with low- or intermediatepretest probability and a positive D-dimer, or high pretest
probability (Figure 2). Contrast-enhanced chest computed
tomography angiography (CTA) is the gold standard for the
diagnosis of PE due to its sensitivity and specificity profile,
as well as its wide availability across hospitals.5 Ventilation/
perfusion scintigraphy (V/Q scan) may be used for pregnant
women, patients with contraindications to iodinated contrast,
such as contrast-induced anaphylaxis or significant renal insufficiency, or when patients cannot be moved for CTA (when
portable V/Q scan is available). Transthoracic echocardiography should also be considered in higher risk patients with PE,
including patients with high pretest probability of PE but with
hemodynamic instability and inability to travel for CTA.
Transthoracic echocardiography provides an assessment of
right ventricular (RV) structure and function as well as an
assessment for intracardiac thrombus-in-transit. Right ventricular “abnormal” may include right heart dilation, interventricular septal compression, increased tricuspid regurgitation, RV
hypokinesis or presence of McConnell’s sign, which refers to a
regional pattern of RV free wall dysfunction with sparing of the
apex.19,20 Duplex leg ultrasonography may be a complimentary
method to investigate for evidence of VTE when PE is suspected and pulmonary vascular imaging cannot be performed.
Once a PE has been confirmed, risk stratification is necessary to determine appropriate therapy. Risk stratification is
primarily based on the ability of the RV to overcome the afterload caused by the thrombus. Acute PE in the presence of
hypotension (defined as systolic blood pressure [SBP] <90
mm Hg for >15 minutes, a drop in SBP of 40 mm Hg or more
from baseline, or requiring hemodynamic support) is considered high-risk (massive) PE.4 In the absence of hypotension,
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further stratification by use of biomarkers, imaging (CTA or
echocardiography), and the Pulmonary Embolism Severity
Index (PESI) or simplified PESI (sPESI) can be performed.5
As none of these factors or scores definitively determines prognosis, clinician gestalt also plays an important role.21 The PESI
and the sPESI represent a validated clinical scoring system that
predict 30-day mortality, with sPESI being a simpler, more
practical clinical approach.22 Intermediate-risk (submassive)
PE patients have PESI class III-V or sPESI 1 or RV dilation
or dysfunction by CTA or echocardiography, or the presence of
positive biomarkers suggestive of myocardial injury (troponin)
or myocardial distention (brain natriuretic peptide [BNP] or
N-terminal pro-BNP).5 Further classification by the ESC of
intermediate-risk PE into intermediate-high risk (presence
of both RV dysfunction on imaging and biomarker elevation)
or intermediate-low risk (either RV dysfunction or biomarker
elevation)5 may help gauge risk of decompensation and suggest
the possible need for more aggressive PE treatment. Hemodynamic decompensation may be evidenced by clinical deterioration based on vital signs, worsening of RV dysfunction, tissue
perfusion, and/or gas exchange. The rationale for sub-dividing
intermediate-risk patients into 2 categories is patients with both
RV dysfunction and abnormal biomarkers have much higher
in-hospital mortality compared to either alone which may aid in
the selection of patients in whom more advance therapies could
be considered.23 In addition, adding lactate levels to risk stratification may identify an even higher risk group for early
decompensation. In a study of 496 normotensive patients with
acute PE, the combination of elevated lactic acid, RV dysfunction, and elevated troponin was associated with a 17.9% incidence of in-hospital mortality or nonfatal hemodynamic
collapse.24
Finally, low-risk PE patients are defined as hemodynamically stable with the absence of clinical markers of adverse
prognosis that define intermediate or high-risk PE. In patients
who are hemodynamically stable at diagnosis, no individual
clinical, imaging, or laboratory finding have been shown to
be superior in predicting risk of decompensation. However,
combinations of clinical findings with imaging and laboratory
tests have been proposed and tested in registries and cohort
studies in attempt to provide enhanced risk stratification.5,25,26
Many low-risk PE patients may be safe for early discharge
without admission to the hospital. In a meta-analysis of 1657
low-risk patients with acute PE from 13 studies, there was
similar mortality, recurrent VTE and bleeding with early hospital discharge (<24 hours) compared to routine hospitalization. However, most of these trials were small in size and
included different methods for identification of risk.27 In the
recently presented HoT-PE trial, 525 patients were discharged
home within 24 hours if they had low risk based on modified
Hestia criteria, including hemodynamic stability, free of significant comorbidities, normal RV function, and absence of
thrombus-in-transit on CTA or echocardiogram.28 The ESC
and ACCP guidelines recommend selected low-risk patients
are safe for early discharge.3,5 In addition, selected low risk
patients with sub-segmental PE and no DVT may be at so low
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risk for death or recurrent PE that the risk of anticoagulation
outweighs any benefit. While the quality of data is low, it may
be reasonable to consider omitting anticoagulation in patients
with a single sub-segmental PE, especially if seen only on only
one image, without DVT, no active cancer, and no symptoms.3
Recommendations:
2. Use a combination of low- or intermediate-pretest probability, the PERC rule and D-dimer testing to rule out
PE without imaging.
3. When possible, use CTA to diagnose acute PE in
patients with low or intermediate pretest probability
and a positive D-dimer, or high pretest probability.
4. Echocardiography and/or portable V/Q scan, when
available, should be considered when there are contraindications to or inability to obtain CTA. Additionally,
duplex ultrasonography should be considered to confirm the presence, acuity, and extent of VTE.
5. Once PE is diagnosed, risk stratification is recommended using a composite of clinical appearance, systolic blood pressure, heart rate, respiratory rate, oxygen
requirement, PESI or sPESI, imaging for RV dysfunction (CTA or echocardiography) and/or biomarkers
(troponin, BNP, or NT-pro-BNP).

7
safety profile may also be considered.30 Frontline clinicians are
advised to discuss these options with their consultants (ie, their
PERT team). For low-risk PE, especially when outpatient management is contemplated, multiple factors should be considered
including but not limited to patient comorbidities, patient compliance, affordability and insurance coverage, and drug characteristics and benefits and should also include shared
decision-making with the patient.31 The direct oral anticoagulants offer many advantages and are now considered first-line
therapy for low-risk PE3 and should be considered in intermediate and high-risk PE patients after clinical stability has
been achieved and/or treatment with advanced therapies is
completed.32 Direct oral anticoagulants do not require routine
monitoring of international normalized ratio for safety or efficacy, have a rapid onset of action, short half-life, predictable
pharmacokinetics and pharmacodynamics, fixed dosing, and
fewer drug and food interactions, making them convenient for
both patient and providers. A detailed description of all of the
various anticoagulants is beyond the scope of this article but is
widely available in the literature.33
Recommendations:

The treatment options for PE are wide ranging and include
anticoagulation alone, catheter-directed thrombolysis, fulldose ST, reduced-dose ST, catheter embolectomy, surgical
embolectomy, and/or mechanical circulatory support
devices.

Anticoagulation should be initiated as soon as PE is
diagnosed unless contraindicated.
7. Anticoagulation should be initiated even prior to the
confirmed diagnosis when the clinical suspicion of
acute PE is high and the bleeding risk is low.
8. Utilize evidence-based institution-specific anticoagulation guidelines to assist in anticoagulant choice, dosing,
administration, and appropriate laboratory monitoring
strategies to achieve therapeutic anticoagulation as
quickly as possible.

Anticoagulation. The benefit of early therapeutic anticoagulation
to improve mortality and decrease recurrence in acute PE is
well proven.29 Anticoagulation should be initiated even prior to
the confirmed diagnosis when there is high clinical suspicion of
acute PE and the bleeding risk is low, particularly if results of
diagnostic tests are expected to be delayed.4 Even when additional therapeutic modalities are considered, anticoagulation
should not be delayed unless contraindicated.4,5
Selection of the initial anticoagulation agent is dependent on
many factors, including risk stratification, patient clinical factors (eg, hepatic and renal function and bleeding risk), and
clinician judgment. In the case of intermediate- and high-risk
PE in which advanced therapies such as thrombolysis, catheterbased interventions, surgical pulmonary embolectomy (SPE) or
mechanical circulatory support are being considered, unfractionated heparin (UFH) may be the preferred agent as it allows
for interventional and surgical teams optimal management
flexibility. The dosing and monitoring of UFH should be based
on institution-specific protocols designed to achieve therapeutic anticoagulation as quickly as possible. Aggressive monitoring and dose adjustment are often required to ensure rapid
therapeutic anticoagulation with UFH. Low-molecular weight
heparin with its rapid and reliable bioavailability and excellent

Systemic thrombolysis. Systemic thrombolysis is given to achieve
rapid clot resolution and restoration of pulmonary perfusion
thereby improving ventilation/perfusion matching, and importantly relieving RV afterload, reducing pulmonary vascular
resistance, and thereby improving hemodynamics.5,34,35 Systemic thrombolysis however, is associated with an increase in
hemorrhagic complications including intracranial hemorrhage
(ICH).3-5,36,37
The decision to administer ST therapy in patients with PE
should be based on the delicate balance between a patient’s
clinical and hemodynamic status and individualized risks of
bleeding. There are several populations in which this therapy
may be considered: cardiac arrest with known or suspected PE,
right-heart thrombus (RHT) or thrombus-in-transit, high-risk
PE, and selected intermediate-high-risk PE cases with low risk
of bleeding (Figure 3).
When confirmed or highly suspected PE is felt to be the
precipitant of cardiac arrest, ST with tissue plasminogen activator (tPA) via bolus or rapid infusion, or tenecteplase via
bolus, have been reported to increase the rate of return of
spontaneous circulation and survival in nonrandomized observational trials.38-42 In some reports, resuscitative measures

Treatment of Pulmonary Embolism
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Table 2. Absolute and Relative Contraindications to Thrombolysis.
Absolute contraindications to systemic thrombolysis
Active bleeding
Prior intracranial hemorrhage
Ischemic stroke within 3 months
Suspected or confirmed aortic dissection
Recent brain or spinal surgery
Recent head or facial trauma
Intracranial neoplasm, vascular malformation, aneurysm, or any
other structural brain disease
Relative contraindications to systemic thrombolysis
Age > 75
Total body weight < 60 kg
Known bleeding diathesis or acquired coagulopathy
Platelet count < 100 000
Coagulopathy (INR > 1.7)
Uncontrolled hypertension (SBP > 180 mm Hg /DBP > 110 mm Hg)
Recent significant nonintracranial bleeding (within 1 month)
Recent major surgery, invasive procedure, and/or trauma (within
1 month)
Current pregnancy or childbirth (within 1 week)
History of remote ischemic stroke (>3 months)
Abbreviations: DBP, diastolic blood pressure; INR, international normalized
ratio; kg, kilograms; SBP, systolic blood pressure.

have continued for up to 30 minutes after thrombolytic administration with successful outcomes.39,43
In high-risk PE, ST is recommended when there are no
contraindications (Table 2),3-5 as it has been shown to reduce
total and PE-related mortality and PE recurrence when compared to UFH alone.36,44 The Food and Drug Administration
(FDA) recommended dose of tPA is 100 mg over 2 hours. In
patients with relative contraindications to ST, a reduced-dose
of 50 mg over 2 hours has been suggested as an alternative to
full-dose ST, with similar improvements in obstruction, perfusion, PA pressure, and RV size with fewer bleeding complications, although data supporting this approach is limited.45
There is no standardized approach on anticoagulation management during thrombolysis, but a reasonable approach is to hold
UFH during the thrombolytic infusion and resume without a
bolus once the partial thromboplastin time is less than twice
control (Supplemental Material).46
Successful use of ST has been reported in a subset of
patients with RHT. 47 Also in retrospective studies of
thombus-in-transit, ST was associated with improved survival
when compared to either anticoagulation therapy or
surgery.48,49
In intermediate-risk PE, the use of ST is more controversial.
Various reports have suggested that ST reduces the risk of
clinical decompensation compared to anticoagulation
alone.37,50 However, in the largest trial to date, the PEITHO
trial, the decreased risk of clinical decompensation was not
accompanied by a decrease in mortality, and was associated
with an increased risk of hemorrhagic stroke. A randomized
trial comparing full-dose to reduced-dose ST in patients with
intermediate or high-risk PE demonstrated similar improvements in a host of surrogate end points including metrics of
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RV dysfunction or PA pressure change with small differences
in bleeding favoring the reduced-dose strategy.45 Reduceddose ST may be considered in select patients with
intermediate-high risk PE and evidence of clinical decompensation after starting anticoagulation based on their symptoms,
vital signs, tissue perfusion, or gas exchange indicators, and
who have low risk of bleeding. 3-5,51 The impact of ST
approaches on long-term mortality, dyspnea, RV dysfunction,
and/or incidence of chronic thromboembolic pulmonary hypertension (CTEPH) in intermediate-risk PE patients is controversial.51,52 Full-dose ST showed a decreased composite outcome
of functional capacity, self-perception of physical health and
quality of life at 90-days (Treatment of submassive PE with
tenecteplase or placebo: cardiopulmonary outcomes at 3
months: multicenter double-blind, placebo-controlled randomized trial [TOPCOAT] trial)53 and a reduced-dose ST showed
a sustained reduction in PA pressure at 28 months, but this was
by echocardiography and thus must be interpreted with caution
(Moderate PE treated with thrombolysis [MOPETT] trial).51
However, in a long-term study, with a 37-month median follow
up time, ST did not affect mortality rates, residual dyspnea or
RV dysfunction in intermediate-risk PE.52 Thus, the decision to
use this approach in an intermediate-risk PE patient should be
highly individualized. Systemic thrombolysis is not recommended for clinically stable patients with minor RV dysfunction or minor myocardial necrosis.4
Recommendations:
9.

Consider full-dose ST in:
9.1 High-risk PE without contraindications to ST

10.

Consider reduced-dose ST in:
10.1 High-risk PE with relative contraindications to
thrombolysis
10.2 Selected intermediate-high risk PE with
evidence of or risk of clinical deterioration
based on vital signs, severity of RV dysfunction, tissue perfusion, and/or gas exchange,
and presence of low bleeding risk.

11.

Consider ST in patients with cardiac arrest and suspected PE
Consider ST in selected patients with intermediate or
high-risk PE with thrombus-in-transit.

12.

Catheter-Directed Therapy
Catheter-directed thrombolysis. Catheter-directed thrombolysis
(CDL) is performed using dedicated 4-6F multi-side-hole infusion catheters to deliver low-dose thrombolytics directly into
the PE. The EkoSonic (EKOS/BTG, Bothell, Washington)
ultrasound-assisted catheter-directed thrombolysis (UCDL)
system is FDA approved for treatment of acute PE.54 This
device consists of a conventional infusion catheter that contains
an inner cable, which transmits high-frequency, low-power
ultrasound waves, with the hypothesis that this will separate
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fibrin strands, enhancing the penetration of the thrombolytic
agent into the emboli. In the 59 intermediate-risk PE patients
who were randomized in the Ultrasound Accelerated Thrombolysis of PE trial, UCDL together with UFH reversed RV
dilation faster than anticoagulation alone in the first 24 hours,
without an increase in bleeding.55 In the SEATTLE II registry,
150 patients with high or intermediate-risk PE treated with
UCDL had low in-hospital mortality and significant early
reductions in pulmonary pressures, RV size, and obstruction
index, with a low bleeding rate and no ICH.56 Similar findings
were noted in 101 consecutive patients treated with CDL in the
PERFECT registry, and no difference was found between CDL
and UCDL (EKOS).57 In a meta-analysis of 860 patients undergoing CDL for PE, there were very low rates of ICH (0.35%)
and major vascular complications (4.65%) with consistent
early reductions in RV/left ventricular (LV) ratio and RV
systolic pressure.58 These studies underscore the relative
safety and efficacy of CDL, and this strategy may be considered in addition to anticoagulation in select patients with
intermediate-high risk and high-risk PE, particularly those
with evidence of clinical deterioration based on symptoms,
vital signs, severity of RV dysfunction, tissue perfusion or gas
exchange, and high risk of bleeding. Clearly availability of
both expertise and rapid mobilization of catheterization
laboratory or operating room facilities are vital in the
decision-making process. (Figure 3) It is unknown how the
safety and efficacy of CDL compares to reduced dose ST for
patients with intermediate and high-risk PE.
The optimal catheter and dose of thrombolytic agent and
UFH for CDL remains unknown. No significant differences
have been shown between UCDL (EKOS) and CDL, but no
randomized head-to-head studies have been conducted.57-61
As UCDL is significantly more expensive than CDL, the
ongoing randomized standard vs. ultrasound-assisted catheter
thrombolysis for submassive PE (SUNSET sPE) trial
(NCT02758574) is investigating the value of ultrasoundfacilitated strategies in CDL.62 Traditionally, the most common dose of tPA has been 0.5 to 1 mg/hour per catheter for a
total dose of 12 to 24 mg delivered over a 24 hours infusion.55
More recently, the optimum duration and dose of r-tPA with
the acoustic pulse thrombolysis procedure for submassive PE
(OPTALYSE PE) trial included even smaller doses of tPA (824 mg) with shorter infusions times, suggesting similar
improvements in RV/LV ratio to higher dose EKOS regimen,
but larger confirmatory studies should be considered.63 In
addition, the optimal UFH dose during CDL is unknown, but
the above studies typically used either a fixed dose of 500 to
1000 units/hour or a low intensity protocol targeting anti-Xa
therapeutic range 0.2 to 0.5 units/mL or PTT 40 to 60 seconds
during tPA infusions (note that the range may vary between
assays). These 2 approaches are used by the majority of clinicians in the PERT consortium (Supplemental Material). Utilization of CDL in intermediate-high risk PE patients
currently varies at different institutions; this remains an area
in need of additional research.
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Catheter embolectomy. Percutaneous pulmonary embolectomy
is largely reserved for selected patients with contraindications
to thrombolysis and/or failure of thrombolysis, when surgical
embolectomy is not available, and if the percutaneous interventional equipment and expertise is available at the treatment
facility (Figure 3).4,5 Given the lack of data and the absence
of a standard approach to catheter embolectomy, selection of
patients for such treatment is best undertaken after multidisciplinary discussions among specialists with expertise in PE
treatment and in centers familiar with its techniques.64
The Flowtriever system (Inari Medical, Irvine, California)
consists of a large aspiration catheter with 3 self-expanding
nitinol disks that are unsheathed to engage the emboli once
inside the desired PA branch.65 Simultaneous manual aspiration and withdrawal of the disks through the 20Fr guide catheter allow for partial clot extraction. The recently completed
prospective Flowtriever Pulmonary Embolectomy Clinical
Study (FLARE trial), showed a significant reduction in RV/
LV ratio in a series of 106 patients, of whom 104 were treated
with catheter embolectomy alone without CDL as an adjunctive technique (unpublished data, presented at Society for Cardiovascular Angiography and Interventions, Scientific Sessions
2018). There was an adverse event rate of 3.8% using this large
device, and no cases of ICH or access site bleeding, and only
one bleeding event. Though limited by its single-arm nature
and its lack of long-term outcome data, the FLARE trial
demonstrates mechanical thrombectomy is feasible and safe.
How this will impact long-term outcomes such as mortality or
the development of CTEPH is unknown.
The Penumbra Indigo embolectomy system (Penumbra Inc,
Alameda, California) works on the principle of thrombus
aspiration and consists of an 8Fr angled or straight catheter that
is connected to a suction pump. The data to support the use of
the Penumbra catheter in acute PE are limited to case reports,66
but a prospective multicenter trial investigating the safety and
efficacy of this catheter is ongoing (NCT03218566).
The AngioVac catheter (Angiodynamics, Latham, New
York) is a 22F catheter that removes embolic material through
a centrifugal pump with blood returned via a venous reinfusion
cannula such as is used in cardiopulmonary bypass. There are
no large case series or randomized trials, and published experience is limited to case reports and small case series. AngioVac is best utilized with inferior vena cava or intracardiac
thrombus, as accessing the pulmonary arterial tree using currently available devices is technically difficult and may incur in
increased complications.
The Angiojet rheolytic thrombectomy system has been
extensively reported upon for the treatment of acute PE.
Despite a large global experience, there have been numerous
adverse events reported with its use including arrhythmias,
hemodynamic compromise, and even death. At present there
is currently a black label warning from the FDA regarding its
use in the pulmonary circulation.67,68
Utilization of catheter embolectomy in intermediate-high
risk PE patients currently varies at different institutions; this
remains an area in need of additional research.
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Recommendations:
13. Consider CDL in:
13.1 Intermediate-high risk PE with risk for clinical
deterioration based on vital signs, severity of
RV dysfunction, tissue perfusion, and/or gas
exchange, and without absolute contraindication to thrombolysis.
13.2 High-risk PE with relative contraindications to
ST.
14. Consider catheter embolectomy in:
14.1 Intermediate-high risk PE with risk for clinical
deterioration based on vital signs, severity of
RV dysfunction, tissue perfusion, and/or gas
exchange, with absolute or relative contraindications to thrombolysis.
14.2 High-risk PE with absolute contraindications
to ST.
14.3 After failed ST or CDL.
14.4 Thombus-in-transit in the right atrium or right
ventricle (AngioVac system).

Surgical Embolectomy
Current consensus clinical guidelines and scientific statements
from the AHA,4 ACCP,3 and ESC5 recommend SPE in patients
with high-risk and intermediate-high risk PE with absolute
contraindications to thrombolysis, failed thrombolysis or cardiogenic shock that can lead to death before thrombolysis can
take effect. The PERT treatment algorithms are in line with
these society recommendations (Figure 3).
In the past, SPE was associated with high perioperative
mortality, although in more recent case series mortality was
reported at 4% to 11%, likely reflecting a change in patients
selected for surgery and advances in technique.69-71 Preoperative thrombolysis increases the risk of surgical bleeding but
does not pose an absolute contraindication to SPE. Survival
depends on patient comorbidities, hemodynamic compromise
prior to surgery and the center’s experience in performing the
procedure.72-74 Patients with central emboli, such as a saddle
PE or those with right atrial thrombus, are considered appropriate candidates for SPE, although such patients should be
compromised enough to require more aggressive therapy than
anticoagulation or catheter embolectomy.75,76 There are no
randomized trials comparing ST to SPE, although both improve
RV function and PA systolic pressures.77 Surgical pulmonary
embolectomy is associated with a decreased risk of major
bleeding compared to ST.70
Right heart thrombi or thrombus-in-transit has been reported
in 2.6% to 4% of PE patients and has been associated with 2 to
3 fold higher mortality than acute PE without RHT.78-82 While
the optimal treatment for RHT is unknown, patients treated
with anticoagulation alone appear to have a higher mortality
than patients treated with ST or SPE.49,79,81 Given the high
short-term mortality especially within the initial 24 hours,

consultation with multidisciplinary PERT is important when
considering surgical, medical, and endovascular options for
these patients. The size of the RHT and the embolic burden
and reserve should be considered; very small RHT may be best
treated conservatively particularly when the overall clot burden
is low. Thrombus-in-transit across a patent foramen ovale
(PFO) represents a unique subgroup of RHT. While the optimal
treatment for these patients is unknown, SPE is probably the
preferred treatment given the high risk for stroke and/or ICH
with thrombolysis, endovascular therapies, and/or anticoagulation alone.
Recommendation:
15.

Consider SPE in:
15.1 High-risk PE with contraindications to, or
failure of ST or CDL.
15.2 Intermediate-high risk PE, with contraindications to, or failure of ST or CDL, with risk for
clinical deterioration based on vital signs,
severity of RV dysfunction, tissue perfusion,
and/or gas exchange.
15.3 Right-heart thrombi, especially with large
thromboembolic burden.
15.4 Thrombus-in-transit across a patent foramen
ovale (PFO).

Mechanical Hemodynamic Support
Mechanical circulatory support should be considered for
patients with high-risk PE and cardiogenic shock with cardiac
arrest or shock refractory to low-dose inotropes or with failure
of thrombolysis (Figure 3). When the acute increase in RV
afterload exceeds the contractile reserve of the thin-walled
right ventricle, this can result in decreased cardiac output and
hemodynamic collapse. The acute RV volume/pressure overload also impairs LV output, increasing the potential for hypotension. While there are no published randomized trials
examining the role of mechanical circulatory support in PE,
multiple uncontrolled case series have demonstrated favorable
outcomes with its use.83-85 Mechanical support may be used in
conjunction with ST, catheter-directed therapy, or SPE. There
are 3 primary devices available utilizing 2 general modes of
support.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
Veno-arterial extracorporeal membrane oxygenation (VAECMO) is effective when used for high-risk PE associated with
higher survival rates than those achieved when VA-ECMO is
used for other common causes of cardiogenic shock.86,87 Survival rates range from 36% to 95% in various case series.84,87-91
In experienced centers, VA-ECMO can be initiated rapidly via
the percutaneous insertion of a 25 to 29F venous cannula and a
15 to 17F arterial cannula. An oxygenator is present in the
circuit providing oxygenation independent of pulmonary blood
flow or RV function. Rates of access site complications,
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including limb ischemia and hemorrhage, vary widely but may
occur in up to 33% of patients.84,91-94 Veno-arterial extracorporeal membrane oxygenation has been successfully used in
combination with multiple treatment modalities, including
thrombolysis, and surgical or catheter embolectomy.84,88,95102
The median duration of ECMO in these series is 4 to 6
days, and together with other PE therapy, allow time for RV
recovery.84,91
Right ventricular assistance to augment antegrade flow. The
Impella RP (Abiomed, Danvers, Massachusetts) is an axial
flow pump placed percutaneously across the pulmonary valve
via a 23Fr sheath in the femoral vein. The pump is capable of
delivering 4 L of flow through the right heart. There is however, no oxygenator in this circuit, which limits its use in
severely hypoxic patients. The TandemHeart Protek Duo (CardiacAssist, Pittsburgh, Pennsylvania) is an extracorporeal centrifugal pump utilizing a 29Fr dual lumen catheter placed
percutaneously through the internal jugular vein into the PA.
An oxygenator may be added to the circuit if hypoxia is present. There are limited single center case reports describing the
use of these devices (Impella RP or TandemHeart Protek Duo)
in patients with high-risk PE.103
The choice of mechanical circulatory support should be
based on the center experience and device-specific
characteristics.
Recommendation:
16. Consider mechanical hemodynamic support in highrisk PE with cardiac arrest, refractory shock, and/or
contraindications to or failure of ST.

Inferior Vena Cava Filters
Inferior vena cava (IVC) filters should be considered in patients
with acute PE and contraindications to anticoagulation and
considered in those with recurrent PE despite anticoagulation.3,5,104 For patients with acute PE who tolerate anticoagulation, the routine use of an IVC filter is not recommended.3,5 A
randomized trial of 400 patients with PE found that placement
of retrievable IVC filters in addition to anticoagulation for 3
months did not reduce recurrent PE or mortality.105 However, it
is feasible that this trial was not enriched with potential candidates who could benefit, such as iliofemoral vein DVT. On the
contrary, registry studies have suggested that patients after
SPE106 and those with high-risk PE have lower rates of recurrent PE and mortality when an IVC filter is placed, but these
findings have not been verified in prospective trials.3,107
Furthermore, in these registries it is unknown if findings reflect
patient selection bias or true benefit from the filter.
Free-floating proximal end DVT are more likely to embolize prior to presentation than those with occlusive
thrombi.108,109 Consideration for insertion of IVC filter should
be given when large, free-floating, proximal DVT is
identified.110
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Nearly all IVC filters currently being placed are retrievable.
When a retrievable filter is placed, patients must be assessed
for removal of the filter at the earliest opportunity. Prolonged
filter implantations have been associated with higher retrieval
failure and other complications, including filter migration, tilting or deformation, penetration of the cava wall by filter limbs,
fracturing of the filter, embolization of fragments, or thrombosis of the device.111,112
Recommendation:
17.

18.

Consider an IVC filter for patients with contraindications to or failure of therapeutic anticoagulation and
for highly selected patients with intermediate or highrisk PE.
Consider an IVC filter in select patients when large,
free-floating, proximal DVT is identified.

Pulmonary Embolism Follow-Up
An important component of a PERT program is assuring appropriate follow up care of patients following hospitalization for
acute PE. Although, there are no formal guidelines on specific
post-PE follow up, we propose a consensus-based approach
(Figure 4). The primary goal of an outpatient follow-up clinic
is to assess the patient for persistent or recurrent symptoms,
decide on appropriate type, dosage and duration of anticoagulation, monitor medication compliance and tolerance, evaluate
for underlying thrombophilia or age-appropriate cancer screening, assist with temporary IVC filter retrieval, and identify
sequelae of PE, such as post-PE syndrome, chronic thromboembolic disease (CTED) or CTEPH. A detailed discussion
regarding the optimal duration and type of anticoagulation as
well as thrombophilia testing and cancer screening is beyond
the scope of this manuscript. Timing of follow-up is based on
the patient’s severity of illness at presentation, hospital course,
and clinical condition on discharge. The ideal time for the
initial visit is individualized, and generally ranges from 2
weeks to 3 months depending on patient characteristics and
on local resources.
A large retrospective, insurance claims-based study of 7068
incident PE patients, found that most patients with persistent
symptoms following a PE did not undergo any further imaging
or diagnostic studies.113 Persistent symptoms, such as dyspnea,
fatigue, lightheadedness or leg edema, merit follow up, particularly if present after 3 months of anticoagulation.
There are no clear guidelines on post-PE imaging but most
agree that repeat lung imaging (with a CTA or V/Q scan) and
echocardiography, and obtaining an objective assessment of
the patient’s physiologic and functional capacity (with 6minute walk testing or cardiopulmonary exercise test) should
be considered in patients whose symptoms do not resolve. The
timing of such testing is individualized; most would consider
testing 3 months after the PE diagnosis.
Abnormal follow-up echocardiography or V/Q scan should
raise concern for the development of CTED or CTEPH. Both of
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these entities can have clinical significance and are considered
part of the post-PE syndrome, defined as any functional limitation following an acute PE.114,115 Chronic thromboembolic
disease is characterized by presence of pulmonary vascular
obstruction without pulmonary hypertension.115,116 Chronic
thromboembolic pulmonary hypertension is pulmonary hypertension caused by chronic organized thrombi obstructing the
pulmonary arteries. Chronic thromboembolic pulmonary
hypertension is defined as mean PA pressure 25 mm Hg with
a pulmonary capillary wedge pressure <15 mm Hg and at least
one segmental perfusion defect detected by V/Q scan, CTA or
pulmonary angiography after 3 months of effective anticoagulation. Although rare, CTEPH can lead to RV failure if not
diagnosed and treated appropriately. If CTEPH is suspected
or confirmed, the patient should be referred to an expert
CTEPH center.
A dedicated outpatient follow-up clinic by the PERT may
provide an opportunity for ensuring standardized follow-up
testing and facilitate comprehensive long-term PE care.
Recommendations:
19.

Pulmonary embolism patients should have a short
interval follow up visit (2 weeks-3 months) post-PE,
or sooner if symptoms or patient complexity suggests
the need for this. Expert follow-up with the PERT
team is recommended.
20. The initial post-discharge visit should focus on the
patient’s clinical status, anticoagulation regimen
(type, dose, duration, compliance, and tolerance), consideration for filter removal, evaluation of thrombophilia and age-appropriate cancer screening.
21. Patients with persistent or recurrent symptoms, particularly after 3 months, merit follow-up testing.
22. If CTEPH is highly suspected or confirmed, the patient
should be referred to an expert CTEPH center

Conclusion
Although PE is a leading cause of death worldwide, controversies regarding treatment and follow-up persist. This document
describes the consensus algorithms for the diagnosis, treatment,
and follow-up of acute PE using the multidisciplinary approach
of the PERT consortium and its members.
The treatment of acute PE is rapidly evolving and clinical
practice will likely benefit from the input from numerous medical specialties. The consensus practices provided in this document represent the cohesive, collective, and collaborative
recommendations of the PERT consortium. Though the PERT
concept is relatively novel, research regarding how PERTs can
impact both early and long-term outcomes of PE patients is
ongoing.
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